Biobanking as an Enabling Technology for Biomarker Research.
A Collaborative Approach in Translational Medicine.
Pharma research requires access to materials from today's gold standard of medical care to discover the next generation of therapeutics.


Pharma research requires access to materials from today's gold standard of medical care to discover the next generation of therapeutics.
Arndt A P Schmitz
Global Drug Discovery
Bayer Schering Pharma AG
Germany.
With the better understanding of pharmacokinetics and pharmacodynamics, most of the new anaesthesia drugs cater to the demands of day care surgeries and primarily aim at an early and uneventful recovery.
Swati Daftary
Consultant Anaesthesiologist
Jaslok Hospital &
India.
In theory, there exist almost infinite number of potential vaccine platforms. In addition, for each such platform, there are many different possible engineering that could lead to different vaccine properties. So, how these be compared? The answer in part lies in standardisation of the process.
David Klatzmann
Professor
Immunology
Director
Immunology
Immunopathology,
Immunotherapy
Research Laboratory
Pitié-Salpêtrière Hospital
France
As the number of candidate vaccines approaching human trials increases, vaccine researchers should consider all collaborative research models, as well as look to their colleagues in prevention sciences for collaboration and to learn how to effectively conduct prevention trials.
Janet Robinson
CFHI Director of Research
Asia Pacific Region
Global Director
Laboratory Sciences
Thailand
In life sciences, traditional supply chains were designed from the inside-out perspective. To adaptively meet actual demand from the customer and translate it into global trade-offs, supply chains need to be designed from an outside-in perspective.
Hussain Mooraj
Vice President
Wayne McDonnell
Research Director
Healthcare & Life Sciences
AMR Research
USA
Issues like approval delays, deficiencies of functioning of CROs and other stake holders, liabilities and compensation to injured subjects, insurance issues etc still remain in India, which has made multinational companies to rethink on opting for India to conduct clinical trials in India recently. There is a need for a law to ensure that the people who undergo clinical trials are not exploited and should be well informed about risk as well to provide clarity on regulations.
Milind Antani
Head
Pharma & Life Science
Practice Groups
Gowree Gokhale
Partner
Nishith Desai Associates
India
Despite the advantages of outsourcing to China, foreign sponsors must overcome several hurdles including significant linguistic and cultural barriers. Companies must address these issues to ensure effective communication with patients, clinical trial staff, ethics committees, and regulatory authorities.
Karen I Politis Virk
Director
Biotech & Pharmaceutical
Research
Language Connections
USA
In the Indian scenario, teachers are overburdened and are involved in too many non-academic activities resulting in poor research output. There are only a handful of universities and institutions with a serious focus on research.
R S Gaud
Dean, School of Pharmacy &
Technology Management
SVKM's Nursee Monji
Institute of
Management Studies
University
India.
Access to accurate real-time information during every phase of development can significantly improve the effectiveness of strategic decision-making, increasing the likelihood of long-term success.
Alan S Louie
Research Director
Health Industry Insights
IDC Company
USA